Human SAA1-derived amyloid deposition in cell culture: a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium

References

• Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283–7
   PubMed Web of Science ®Google Scholar
• Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988;28:317–24
   PubMed Web of Science ®Google Scholar
• Lachmann, HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–71
   PubMed Web of Science ®Google Scholar
• Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435–40
   PubMed Web of Science ®Google Scholar
• van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87–98
   PubMed Web of Science ®Google Scholar
• Verine J, Mourad N, Desseaux K, Vanhille P, Noel LH, Beaufils H, Grateau G, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007;81:1798–809
   Google Scholar
• Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:408–13
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24–9
   PubMed Web of Science ®Google Scholar
• Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991;147:1261–5
   PubMed Web of Science ®Google Scholar
• Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993;268:25624–31
   PubMed Web of Science ®Google Scholar
• Jiang SL, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms. J Immunol 1995;154:825–31
   PubMedGoogle Scholar
• Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apolipoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 1979;76:4092–6
   PubMed Web of Science ®Google Scholar
• de Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231–4
   PubMed Web of Science ®Google Scholar
• Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111–22
   PubMed Web of Science ®Google Scholar
• Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068–76
   PubMed Web of Science ®Google Scholar
• Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, Yalçinkaya F; International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706–12
   PubMed Web of Science ®Google Scholar
• Maury CP, Aittoniemi J, Tiitinen S, Laiho K, Kaarela K, Hurme M. Variant mannose-binding lectin 2 genotype is a risk factor for reactive amyloidosis in rheumatoid arthritis. J Intern Med 2007;262:466–9
   PubMed Web of Science ®Google Scholar
• Westermark P, Westermark GT. Reflections on amyloidosis in Papua New Guinea. Phil Trans R Soc B 2008;363:3701–5
   PubMedGoogle Scholar
• Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, Nishinarita M, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999;105:360–6
   PubMed Web of Science ®Google Scholar
• Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S. Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003;42:800–5
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology 2006;45:43–9
   PubMed Web of Science ®Google Scholar
• Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. A temporal and ultrastructural relationshipship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991;39:1321–30
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 2007;14:21–32
   PubMed Web of Science ®Google Scholar
• McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 1988;256:775–83
   PubMed Web of Science ®Google Scholar
• Elimova E, Kisilevsky R, Ancsin JB. Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine switch. FASEB J 2009;23:3436–48
   PubMedGoogle Scholar
• Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li JP. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein promoting SAA aggregation. J Biol Chem 2012;287:25669–77
   PubMed Web of Science ®Google Scholar
• Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004;18:1749–51
   PubMed Web of Science ®Google Scholar
• Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, et al. In vivo fragmentation of heparan sulfate by overexpression of heparanase renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005;102:6473–7
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999;155:123–33
   PubMed Web of Science ®Google Scholar
• Magy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B. Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 2007;14:51–63
   PubMed Web of Science ®Google Scholar
• Pilling D, Vakil V, Gomer RH. Improved serum-free culture conditions for the differentiation of human and murine fibrocytes. J Immunol Methods 2009;351:62–70
   PubMed Web of Science ®Google Scholar
• Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994;1226:323–9
   PubMed Web of Science ®Google Scholar
• Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol 1999;309:3–25
   PubMed Web of Science ®Google Scholar
• Lendrum AC, Slidders W, Fraser DS. Renal hyaline. A study of amyloidosis and diabetic fibrinous vasculosis with new staining methods. J Clin Pathol 1972;25:373–96
   PubMed Web of Science ®Google Scholar
• Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011;11:427–35
   PubMed Web of Science ®Google Scholar
• Bellini A, Mattoli S. The role of the fibrocyte, a bone-marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007;87:858–70
   PubMed Web of Science ®Google Scholar
• Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, Rauterberg J, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol 2008;180:5707–19
   PubMedGoogle Scholar
• Patel H, Bramall J, Waters H, DeBeer MC, Woo P. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 1996;318:1041–9
   PubMed Web of Science ®Google Scholar
• Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008;83:1323–33
   PubMed Web of Science ®Google Scholar
• Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166–73
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723–37
   PubMed Web of Science ®Google Scholar
• Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994;180:203–9
   PubMed Web of Science ®Google Scholar
• Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O’Hara R, FitzGerald O, Veale DJ, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB dependent signal transduction pathway. Arthritis Rheum 2006;54:105–14
   PubMedGoogle Scholar
• Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006;177:5585–94
   PubMedGoogle Scholar
• Lee HY, Kim M-K, Park KS, Park KS, Bae YH, Yun J, Park J-I, et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005;330:989–98
   PubMed Web of Science ®Google Scholar
• He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003;101:1572–81
   PubMed Web of Science ®Google Scholar
• Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 2004;17:145–56
   PubMed Web of Science ®Google Scholar
• Lee HY, Kim SD, Shim JW, Lee SY, Lee H, Cho KH, Yun J, et al. SAA induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 2008;18:4332–9
   Google Scholar
• Franco AG, Sandri S, Campa A. High-density lipoprotein prevents SAA-induced production of TNF-alpha in THP-1 monocytic cells and peripheral blood mononuclear cells. Mem Inst Oswaldo Cruz 2011;106:986–92
   PubMedGoogle Scholar
• Kinkley SM, Bagshaw WLG, Tam S-P, Kisilevsky R. The path of serum amyloid A through peritoneal macrophages. Amyloid 2006;13:123–34
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012;19:5–14
   PubMed Web of Science ®Google Scholar
• Wang L, Lashuel HA, Walz T, Colon W. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA 2002;99:15947–52
   PubMed Web of Science ®Google Scholar
• Wang Y, Srinivasan S, Ye Z, Javier Aguilera J, Lopez MM, Colon W. Serum amyloid A2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer. Biochem Biophys Res Commun 2011;407:725–9
   PubMedGoogle Scholar
• Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171:5537–46
   PubMed Web of Science ®Google Scholar
• Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y, Nakano S, et al. Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 1997;77:525–31
   PubMed Web of Science ®Google Scholar